{
    "info": {
        "nct_id": "NCT04975919",
        "official_title": "A Phase II Study of Venetoclax in Combination With 10-day Oral Decitabine in Relapsed/Refractory Acute Myeloid Leukemia",
        "inclusion_criteria": "* Patients with a diagnosis of relapsed or refractory AML (or biphenotypic or bilineage leukemia including a myeloid component). Patients with isolated extramedullary AML are eligible\n* Age >= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Creatinine < 2 unless related to the disease\n* Direct bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement\n* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement\n* In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents. Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\n* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug\n* Willing and able to provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)\n* Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)\n* Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications as determined by the investigator\n* Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia\n* Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\n* Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection\n* Subject has a white blood cell count > 10 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\n* Nursing women, women of childbearing potential (WOCBP) with positive urine or serum pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception\n\n  * Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients with a diagnosis of relapsed or refractory AML (or biphenotypic or bilineage leukemia including a myeloid component). Patients with isolated extramedullary AML are eligible",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of relapsed or refractory AML",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "biphenotypic or bilineage leukemia including a myeloid component",
                    "criterion": "biphenotypic or bilineage leukemia with myeloid component",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "myeloid component",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "isolated extramedullary AML",
                    "criterion": "isolated extramedullary AML",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing and able to provide informed consent",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to provide informed consent",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to provide informed consent",
                    "criterion": "ability to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... < 3 x ULN unless considered due to leukemic involvement",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) < 3 x ULN unless considered due to leukemic involvement",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine < 2 unless related to the disease",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 2",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Direct bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's disease or leukemic involvement",
            "criterions": [
                {
                    "exact_snippets": "Direct bilirubin < 2 x upper limit of normal (ULN)",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless increase is due to Gilbert's disease",
                    "criterion": "Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "cause of increased direct bilirubin",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless increase is due to ... leukemic involvement",
                    "criterion": "leukemic involvement",
                    "requirements": [
                        {
                            "requirement_type": "cause of increased direct bilirubin",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents. Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
            "criterions": [
                {
                    "exact_snippets": "the interval from prior treatment to time of initiation will be at least 7 days for cytotoxic or non-cytotoxic (immunotherapy) agents",
                    "criterion": "interval from prior treatment to initiation",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "cytotoxic agents",
                                "non-cytotoxic (immunotherapy) agents"
                            ]
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": "absence of rapidly proliferative disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for patients with rapidly proliferative disease is allowed before the start of study therapy, as needed, for clinical benefit and after discussion with the principal investigator (PI)",
                    "criterion": "use of oral hydroxyurea and/or cytarabine before study therapy",
                    "requirements": [
                        {
                            "requirement_type": "drug_type",
                            "expected_value": [
                                "oral hydroxyurea",
                                "cytarabine"
                            ]
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "g/m^2"
                            }
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": "rapidly proliferative disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted",
                    "criterion": "concurrent CNS therapy",
                    "requirements": [
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "CNS prophylaxis",
                                "continuation of therapy for controlled CNS disease"
                            ]
                        },
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator",
                    "criterion": "medical, psychological, or social condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant (patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI)",
            "criterions": [
                {
                    "exact_snippets": "Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant",
                    "criterion": "active graft-versus-host-disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status post stem cell transplant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients without active GVHD on chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD are permitted after discussion with the PI",
                    "criterion": "chronic suppressive immunosuppression and/or phototherapy for chronic skin GVHD",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "chronic suppressive immunosuppression",
                                "phototherapy"
                            ]
                        },
                        {
                            "requirement_type": "GVHD activity",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "discussion with PI",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human immunodeficiency virus (HIV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B (HBV) or hepatitis C (HCV) infection",
                    "criterion": "hepatitis B (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active hepatitis B (HBV) or hepatitis C (HCV) infection",
                    "criterion": "hepatitis C (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus (HIV) infection",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has a white blood cell count > 10 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion)",
            "criterions": [
                {
                    "exact_snippets": "white blood cell count > 10 x 10^9/L",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia",
            "criterions": [
                {
                    "exact_snippets": "symptomatic CNS leukemia",
                    "criterion": "CNS leukemia",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "poorly controlled CNS leukemia",
                    "criterion": "CNS leukemia",
                    "requirements": [
                        {
                            "requirement_type": "disease control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications as determined by the investigator",
            "criterions": [
                {
                    "exact_snippets": "any severe gastrointestinal or metabolic condition which could interfere with the absorption of oral study medications",
                    "criterion": "gastrointestinal or metabolic condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "potential to interfere with absorption of oral study medications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the investigator",
                    "criterion": "investigator determination",
                    "requirements": [
                        {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
            "criterions": [
                {
                    "exact_snippets": "Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide)",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "oral hormonal birth control",
                                "injectable hormonal birth control",
                                "intrauterine device (IUD)",
                                "double barrier methods (e.g., condom with spermicide)"
                            ]
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
            "criterions": [
                {
                    "exact_snippets": "t(15;17) karyotypic abnormality",
                    "criterion": "t(15;17) karyotypic abnormality",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute promyelocytic leukemia (French-American-British [FAB] class M3-AML)",
                    "criterion": "acute promyelocytic leukemia (FAB class M3-AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nursing women, women of childbearing potential (WOCBP) with positive urine or serum pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Nursing women",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential (WOCBP) with positive urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential who are not willing to maintain adequate contraception",
                    "criterion": "contraception willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness to maintain adequate contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must agree to refrain from unprotected sex from initial study drug administration until 90 days after the last dose of study drug",
                    "criterion": "unprotected sex",
                    "requirements": [
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from initial study drug administration"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after the last dose of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male subjects must agree to refrain from ... sperm donation from initial study drug administration until 90 days after the last dose of study drug",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from initial study drug administration"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 90,
                                        "unit": "days after the last dose of study drug"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician",
            "criterions": [
                {
                    "exact_snippets": "active and uncontrolled comorbidities including active uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension despite adequate medical therapy",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV",
                    "criterion": "congestive heart failure (NYHA class III/IV)",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant and uncontrolled arrhythmia as judged by the treating physician",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}